Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still…
Recent Articles
Lagging in the weight-loss market? Take Fosun’s GLP-1 pill
2196.HK
600196.SHG
RELATED ARTICLES
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK600276.SHG - Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
Fosun’s Portuguese makeover moves ahead with $360 million health disposal
0656.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
